# Extension Study of BMN 044 in Duchenne Muscular Dystrophy (DMD)

> **NCT02958202** · PHASE2 · TERMINATED · sponsor: **BioMarin Pharmaceutical** · enrollment: 7 (actual)

## Conditions studied

- Duchenne Muscular Dystrophy

## Interventions

- **DRUG:** BMN 044 IV 6 mg/kg
- **DRUG:** BMN 044 IV 9 mg/kg
- **DRUG:** BMN 044 SC 6 mg/kg

## Key facts

- **NCT ID:** NCT02958202
- **Lead sponsor:** BioMarin Pharmaceutical
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2016-04
- **Primary completion:** 2016-09
- **Final completion:** 2016-09
- **Target enrollment:** 7 (ACTUAL)
- **Why stopped:** Regulatory approval was not obtained for drisapersen, hence BioMarin is stopping the development of all exon skipping oligonucleotides in DMD.
- **Last updated:** 2018-01-26


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02958202

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02958202, "Extension Study of BMN 044 in Duchenne Muscular Dystrophy (DMD)". Retrieved via AI Analytics 2026-06-14 from https://api.ai-analytics.org/clinical/NCT02958202. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*